Analyse ADARx Pharmaceuticals, Inc. (ADRX) — Kairos Score 58/100

À propos de ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

Informations clés

🕴️ Activité des initiés (90 jours)

23 transactions — 5 achats et 0 ventes déclarés par les dirigeants de ADARx Pharmaceuticals, Inc..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur ADRX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

3 articles récents sur ADRX.

• ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
• ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.